DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for intestinal pseudo-obstruction — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntestinal pseudo-obstruction maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intestinal pseudo-obstruction is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
thymidine phosphorylase (TYMP) — TYMP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet tdrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2J0F · 2.31 Å · ligand THYMINE (TDR). Experimental structure, not a prediction.
What the evidence adds up to
Intestinal pseudo-obstruction is a syndrome with many causes, and treatment must be guided by the specific cause and extent of gastrointestinal involvement in each patient. For primary chronic cases, a family history should be taken; if positive, genetic counselling and proper medical management can be offered to newly identified family members.
Cisapride has been used in chronic intestinal pseudo-obstruction with some success, but its use in acute pseudo-obstruction had not been adequately studied as of 2003. One case report describes a patient whose acute intestinal pseudo-obstruction was probably precipitated by pneumonia and sepsis. After initiation of cisapride therapy, the pseudo-obstruction resolved promptly, even as the patient’s overall clinical status progressively deteriorated. The authors implicate cisapride as the cause of improved intestinal function and suggest a trial of cisapride be considered for acute pseudo-obstruction when other therapeutic manoeuvres have failed. This is the second such case reported in the English language literature.
No controlled trials, no randomised data, and no quantitative outcomes such as survival or response rates are provided in these abstracts. The evidence for cisapride in acute pseudo-obstruction rests on two single-case reports. What is still missing is any prospective trial design, adequate sample sizes, and patient stratification by underlying cause.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 2018 · 21 citations
The Use of Pyridostigmine in a Child With Chronic Intestinal Pseudo-Obstruction
AbstractChronic intestinal pseudo-obstruction is a rare disorder that affects the motility of the gastrointestinal tract. It results in acute or subacute intestinal obstruction symptoms in the absence of mechanical lesion. It can lead to intestinal failure in children with significant strain on nutrition, growth, and development. There is no universally agreed protocol for management of chronic intestinal pseudo-obstruction in children, and there is wide variation in clinical practice.
AbstractIntestinal pseudo-obstruction is a syndrome of many causes. Attempts must be made to determine the cause and the extent of the involvement of the gastrointestinal tract in each patient, because they will dictate the method of treatment for that patient. Family history must be taken from all primary chronic intestinal pseudo-obstruction patients. If it is positive, genetic counseling and proper medical management can be given to newly identified cases in the family.
AbstractIntestinal pseudo-obstruction is a syndrome of many causes. Attempts must be made to determine the cause and the extent of the involvement of the gastrointestinal tract in each patient, because they will dictate the method of treatment for that patient. Family history must be taken from all primary chronic intestinal pseudo-obstruction patients. If it is positive, genetic counseling and proper medical management can be given to newly identified cases in the family.
American Journal of Hospice and Palliative Medicine® · 2012 · 1 citations
Clinical Recovery of Chronic Intestinal Pseudo-Obstruction With Cisapride in a Complex Pediatric Patient
AbstractCisapride is a gastrointestinal prokinetic that facilitates or restores motility along the entire gastrointestinal tract. It has been used successfully to treat acute and chronic intestinal pseudo-obstructions (CIPs) in adults, but there is a paucity of literature surrounding the treatment of CIP in pediatric patients and therapies for CIP are limited and their impact is often unsatisfactory. This case report presents the use of cisapride in the management of pseudo-obstruction. Treatment with cisapride substantially improved the patient's symptoms and improved feeding tolerance. It improved his prognosis remarkably and prevented the need for end-of-life care. He experienced no adverse effects throughout the course of therapy. The treatment regimen is discussed in this case report.
Deformación metálica: Técnicas de fabricación, acabado y transformación del fleje, chapa, tubos y alambre · 2003 · 0 citations
El acero inoxidable en la construcción
AbstractCisapride has been used in the treatment of chronic intestinal pseudo-obstruction with some success; however, the use of cisapride in the treatment of acute pseudo-obstruction has not been adequately studied. We describe a case of acute intestinal pseudo-obstruction successfully treated with cisapride. To our knowledge, this is the second such case reported in the English language literature. Our patient's acute intestinal pseudo-obstruction was probably precipitated by pneumonia and sepsis, and the prompt resolution of his intestinal pseudo-obstruction after initiation of cisapride therapy (despite progressive deterioration of his overall clinical status) implicates cisapride as the cause of the improved intestinal function. Therefore, we suggest that a trial of cisapride be considered for patients with acute intestinal pseudo-obstruction when other therapeutic maneuvers have failed.
Zenodo (CERN European Organization for Nuclear Research) · 2018 · 0 citations · open access
Key Mechanisms Of The Emergence Of Acute Intestinal Obstruction And Selection Argumentation Of Therapeutic And Diagnostic Tactics (Literature Review)
AbstractIn this literature review, the main etiological factors of intestinal obstruction, key aspects of a number of mechanisms of development of intestinal obstruction are considered. The problems of modern diagnostics of acute intestinal obstruction of various genesis are considered, including the erased picture of the disease on the basis of which the optimal therapeutic diagnostic algorithms were formed. The argumentation of methods of treatment proceeding from pathogenetic features of the given pathology results.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
